ABSTRACT
Novel conjugates of the antimalarial drug primaquine (compound 1) with ferrocene, named primacenes, have been synthesized and screened for their activities against blood stage and liver stage malaria
in vitro
and host-vector transmission
in vivo
. Both transmission-blocking and blood-schizontocidal activities of the parent drug were conserved only in primacenes bearing a basic aliphatic amine group. Liver stage activity did not require this structural feature, and all metallocenes tested were comparable to or better than primaquine in this regard. Remarkably, the replacement of primaquine's aliphatic chain by hexylferrocene, as in compound 7, led to a ∼45-fold-higher level activity against liver stage parasitemia than that of primaquine.
摘要
合成了抗疟药物伯氨喹(化合物 1)与二茂铁的新型共轭物,命名为二茂铁骁悉,并筛选了其对血期和肝期疟疾的活性。
体外
和宿主-病媒传播
体内
.母体药物的传播阻断和血吸虫杀灭活性只有在含有碱性脂肪胺基团的原烯中才得以保留。肝脏阶段的活性并不需要这一结构特征,所有测试过的茂金属在这方面都与伯氨喹相当或优于伯氨喹。值得注意的是,用二茂铁己基取代伯氨喹的脂肪链(如化合物 7),对肝阶段寄生虫血症的活性比伯氨喹高出 45 倍。